Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 17/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547996 | 0.84 | FFAR4 (0.56) | CHRM4FFAR4 | |
| SCHEMBL12042021 | 0.83 | NOTUM (0.56) | CHRM4FFAR4CHRM2 | |
| SCHEMBL381806 | 0.82 | NOTUM (0.54) | CHRM4FFAR4CHRM2 | |
| SCHEMBL17206997 | 0.82 | CHRM4 (0.55) | CHRM4CHRM2 | |
| SCHEMBL6794719 | 0.81 | FFAR4 (0.51) | CHRM4FFAR4CHRM2 | |
| SCHEMBL13279361 | 0.79 | CHRM4 (0.55) | CHRM4CHRM2 | |
| SCHEMBL17033958 | 0.79 | CHRM4 (0.57) | CHRM4CHRM2 | |
| SCHEMBL12717115 | 0.79 | FFAR4 (0.72) | CHRM4FFAR4CHRM2 | |
| SCHEMBL13279873 | 0.78 | CHRM4 (0.59) | CHRM4CHRM2 | |
| SCHEMBL13279129 | 0.78 | CHRM4 (0.54) | CHRM4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| EP-1718635-A1 | PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082889-A1 | PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-09 | — | — | WO | disclosed |
| EP-1539739-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | CHRM4 2224/4885FFAR4 1356/4885CHRM2 3220/4885 |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | ITGB3, ITGAV, ITGA2B | CHRM4 2224/4885FFAR4 1356/4885CHRM2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.